Skip to main content Accessibility help
×
Home

Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate

  • Anita H. Clayton (a1), Julie C. Locklear (a2), Henrik Svedsäter (a3) and Roger S. McIntyre (a4)

Abstract

Objective

We evaluated sexual functioning from 6 acute, randomized, placebo-controlled studies (6–10 weeks) of once-daily extended release quetiapine fumarate (quetiapine XR) 50, 150, or 300 mg/day as monotherapy (Studies 1–4) or adjunct therapy (Studies 6–7) in major depressive disorder (MDD).

Methods

We present a pre-planned, non-inferiority analysis of quetiapine XR monotherapy versus placebo using Changes in Sexual Functioning Questionnaire (CSFQ) total score change (Studies 1–4). Post hoc analyses evaluated CSFQ total and domain scores for fixed-dose monotherapy (Studies 1–2), modified fixed-dose (Studies 3–4), and adjunct therapy studies (Studies 6–7). CSFQ data for active comparators (duloxetine [Study 2], escitalopram [Study 4]) are reported.

Results

Quetiapine XR monotherapy was non-inferior to placebo for sexual functioning (least squares mean [LSM] difference in CSFQ score change versus placebo, 0.16 [95% confidence interval: −0.59, 0.92]); LSM change in CSFQ score: 1.90, quetiapine XR (all doses) and 1.73, placebo. LSM differences versus placebo (95% confidence interval): 0.18 (−1.40, 1.75), duloxetine (Study 2); 0.16 (−1.77, 2.10), escitalopram (Study 4). LSM differences with adjunct quetiapine XR 150 mg/day (0.52; p = 0.338) or 300 mg/day (0.22; p = 0.679) were comparable with placebo plus antidepressants. Post hoc all-patient and gender-specific analyses were comparable for CSFQ total scores versus placebo with quetiapine XR 50, 150, or 300 mg/day, duloxetine, and escitalopram.

Discussion

Lack of negative effects on sexual functioning in patients with MDD may improve treatment acceptability.

Conclusion

Quetiapine XR (monotherapy or adjunct therapy) had an impact on sexual function that was comparable with placebo.

Copyright

Corresponding author

*Address for correspondence: Anita H. Clayton, MD, Department of Psychiatry and Neurobehavioral Sciences, University of Virginia, 2955 Ivy Road, Northridge Suite 210, Charlottesville, VA 22903, USA. Email AHC8V@virginia.edu

References

Hide All
1. Kennedy, SH, Dickens, SE, Eisfeld, BS, etal. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord. 1999; 56(2–3): 201208.
2. Williams, K, Reynolds, MF. Sexual dysfunction in major depression. CNS Spectr. 2006; 11(8 suppl 9): 1923.
3. Clayton, A, Keller, A, McGarvey, EL. Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord. 2006; 91(1): 2732.
4. Ashton, AK, Jamerson, BD, Weinstein, WL, etal. Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Current Therapeutic Research. 2005; 66(2): 96106.
5. Montejo, AL, Llorca, G, Izquierdo, JA, etal. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001; 62(suppl 3): 1021.
6. Clayton, A, Kornstein, S, Prakash, A, etal. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med. 2007; 4(4 Pt 1): 917929.
7. Clayton, AH, Pradko, JF, Croft, HA, etal. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002; 63(4): 357366.
8. AstraZeneca. Seroquel XR (quetiapine fumarate) extended-release tablets—US prescribing information [Web site]. July 2013. Available at: http://www1.astrazeneca-us.com/pi/seroquelxr.pdf. Accessed September 6, 2013.
9. AstraZeneca UK Limited. Seroquel XL Summary of Product Characteristics (UK) [Web site]. April 26, 2012. Available at: http://www.medicines.org.uk/emc/medicine/21175. Accessed November 16, 2012.
10. Weisler, R, Joyce, M, McGill, L, etal. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr. 2009; 14(6): 299313.
11. Cutler, AJ, Montgomery, SA, Feifel, D, etal. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry. 2009; 70(4): 526539.
12. Bortnick, B, El-Khalili, N, Banov, M, etal. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord. 2011; 128(1–2): 8394.
13. Earley, W, McIntyre, A, Wang, G, etal. Double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD) [Abstract]. Int J Psychiatry Clin Pract. 2008; 12: 332.
14 El-Khalili, N, Joyce, M, Atkinson, S, etal. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010; 13(7): 917932.
15. Bauer, M, Pretorius, HW, Constant, EL, etal. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009; 70(4): 540549.
16. Katila, H, Mezhebovsky, I, Mulroy, A, etal. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry. 2013; 21(8): 17691784.
17. Liebowitz, M, Lam, RW, Lepola, U, etal. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety. 2010; 27(10): 964976.
18. Hu, XH, Bull, SA, Hunkeler, EM, etal. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004; 65(7): 959965.
19. Williams, VS, Baldwin, DS, Hogue, SL, etal. Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey. J Clin Psychiatry. 2006; 67(2): 204210.
20. Sheehan, DV, Lecrubier, Y, Sheehan, KH, etal. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59(suppl 20): 2233.
21. Hamilton, M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23: 5662.
22. Keller, A, McGarvey, EL, Clayton, AH. Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short-form (CSFQ-14). J Sex Marital Ther. 2006; 32(1): 4352.
23. Kennedy, SH. Core symptoms of major depressive disorder: relevance to diagnosis and treatment. Dialogues Clin Neurosci. 2008; 10(3): 271277.
24. Zimmerman, M, Posternak, M, Friedman, M, etal. Which factors influence psychiatrists’ selection of antidepressants? Am J Psychiatry. 2004; 161(7): 12851289.
25. Montejo-Gonzalez, AL, Llorca, G, Izquierdo, JA, etal. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther. 1997; 23(3): 176194.
26. Maguire, GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry. 2002; 63(suppl 4): 5662.
27. Kelly, DL, Conley, RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology. 2006; 31(3): 340346.
28. Fava, M, Dording, CM, Baker, RA, etal. Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies. Prim Care Companion CNS Disord. 2011; 13(1). DOI: 10.4088/PCC.10m00994gre.
29. Montejo, AL, Perahia, DG, Spann, ME, etal. Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder. J Sex Med. 2011; 8(3): 773782.
30. Kennedy, SH, Eisfeld, BS, Dickens, SE, etal. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 2000; 61(4): 276281.
31. Nurnberg, HG. Managing treatment-emergent sexual dysfunction associated with serotonergic antidepressants: before and after sildenafil. J Psychiatr Pract. 2001; 7: 92108.
32. Segraves, RT. Antidepressant-induced sexual dysfunction. J Clin Psychiatry. 1998; 59(suppl 4): 4854.
33. Clayton, AH, Croft, HA, Horrigan, JP, etal. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry. 2006; 67(5): 736746.
34. Perlis, RH, Laje, G, Smoller, JW, etal. Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacology. 2009; 34(7): 18191828.
35. Bishop, JR, Moline, J, Ellingrod, VL, etal. Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825 T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology. 2006; 31(10): 22812288.
36. Cipriani, A, Furukawa, TA, Salanti, G, etal. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009; 373(9665): 746758.

Keywords

Related content

Powered by UNSILO

Sexual functioning in patients with major depressive disorder in randomized placebo-controlled studies of extended release quetiapine fumarate

  • Anita H. Clayton (a1), Julie C. Locklear (a2), Henrik Svedsäter (a3) and Roger S. McIntyre (a4)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.